About: Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model
Creator	Humeau, Laurent Reuschel, Emma Weiner, David Aly, Ahmed Kim, Kevin Zaidi, Faraz Bah, Mamadou Chu, Jacqueline Hart, Robert Xu, Ziyang Perrin, Benjamin Reeder, Sophia Tursi, Nicholas Yilmaz, Ilknur Yun, Kun
source	PMC
abstract	The need for a malaria vaccine is indisputable. A single vaccine for Plasmodium pre-erythrocytic stages targeting the major sporozoite antigen circumsporozoite protein (CSP) has had partial success. Additionally, CD8+ T cells targeting liver-stage (LS) antigens induced by live attenuated sporozoite vaccines were associated with protection in human challenge experiments. To further evaluate protection mediated by LS antigens, we focused on exported pre-erythrocytic proteins (exported protein 1 (EXP1), profilin (PFN), exported protein 2 (EXP2), inhibitor of cysteine proteases (ICP), transmembrane protein 21 (TMP21), and upregulated in infective sporozoites-3 (UIS3)) expressed in all Plasmodium species and designed optimized, synthetic DNA (synDNA) immunogens. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%–88% in non-adjuvanted groups were protected from blood-stage disease following Plasmodium yoelii sporozoite challenge. This study supports the potential of synDNA LS antigens as vaccine components for malaria parasite infection.
has issue date	2020-01-10(xsd:dateTime)
bibo:doi	10.3390/vaccines8010021
bibo:pmid	31936739
has license	cc-by
sha1sum (hex)	25308c7825d20d18494ba38ac49632ebbb14f256
schema:url	https://doi.org/10.3390/vaccines8010021
resource representing a document's title	Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model
has PubMed Central identifier	PMC7157753
has PubMed identifier	31936739
schema:publication	Vaccines (Basel)
resource representing a document's body	covid:25308c7825d20d18494ba38ac49632ebbb14f256#body_text
is schema:about of	named entity 'Challenge' named entity 'Protection' covid:arg/25308c7825d20d18494ba38ac49632ebbb14f256 named entity 'Mouse Model' named entity 'mice' named entity 'antigen' named entity 'liver' named entity 'antigen' named entity 'antigens' named entity 'liver' named entity 'mosquitoes' named entity 'DNA vaccination' named entity 'cell surface marker' named entity 'plasmid' named entity 'gene' named entity 'life cycle' named entity 'parasitemia' named entity 'phenotype' named entity 'long-term' named entity 'protect against malaria' named entity 'Primary antibody' named entity 'sporozoites' named entity 'IL-33' named entity 'CSP' named entity 'Zika' named entity 'IL-33' named entity 'effector' named entity 'immune response' named entity 'cynomolgus macaques' named entity 'vaccination' named entity 'blood smears' named entity 'vaccination' named entity 'Plasmodium' named entity 'Plasmodia' named entity 'infection' named entity 'vaccine' named entity 'RPMI' named entity 'antigens' named entity 'upregulated' named entity 'plasmids' named entity 'liver' named entity 'western blot' named entity 'DAPI' named entity 'adjuvant' named entity 'CD8+' named entity 'vector' named entity 'spleen' named entity 'irradiation' named entity 'infection' named entity 'Tanzania' named entity 'antigens' named entity 'blood stage' named entity 'bar graph' named entity 'vaccination' named entity 'CSP' named entity 'salivary gland' named entity 'flow cytometry' named entity 'IgG' named entity 'antigens' named entity 'antigen' named entity 'Carlsbad, CA' named entity 'negative control' named entity 'attenuation' named entity 'IL-2' named entity 'CD8+ T cells' named entity 'Hepatitis' named entity 'cellular immune responses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software